newsfilter
← Latest News
Business Wire·

Covidien’s Stellarex™ Drug-Coated Angioplasty Balloon Receives CE Mark to Treat Peripheral Arterial Disease Patients

DUBLIN, Ireland--(BUSINESS WIRE)--Covidien plc (NYSE:COV) today announced it has received CE Mark approval for its Stellarex™ drug-coated angioplasty balloon (DCB). The Stellarex™ DCB is used to restore and maintain blood flow to the arteries of the leg in patients with peripheral arterial disease (PAD).